*Created on 2023-12-09, 16:48* 

---
### Pathogenesis
- [[Philadelphia chromosome]]: Chr (9,22) BCR-ABL 
- Other mutations: Atypical CML, which has unfavorable prognosis 
- [[tyrosine kinase]]
- [[tyrosine kinase inhibitors]]

### presentation

| Phase             | Features                                                                                                                                                                                                                                                 |
| ----------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Chronic phase     | Features of [[Granulomatous diseases]] <br> [[Splenomegaly]]                                                                                                                                                                                             |
| Accelerated phase | [[Bone marrow suppression]] except [[Thrombocytosis]] <br> [[Massive splenomegaly]] due to [[Extramedullary Hematopoiesis]] which may lead to [[splenic rupture]] <br> [[Hyperviscosity syndrome]] <br> [[Myelofibrosis]] due to [[Tissue Infiltration]] |
| Blast crisis      | Symptoms resembling [[Acute Leukemia]] <br> [[Pancytopenia]] due to [[Bone marrow suppression]] <br> Severe malaise <br> Subtypes <br> - Myeloid crisis: [[Acute myeloid leukemia]] (2/3rd) <br> - Lymphoid crisis: [[Acute lymphoblastic leukemia]]     |
 
### Diagnosis
- [[Leukocytosis]] with mid-stage progenitor cells
	- Leukocyte alkaline phosphatase: Low 
- [[Flow cytometry]]
	- [[Basophils]] release [[Histamine]]: [[pruritus]]
	- Thrombocytosis
	- Eosinophilia
	- Blast cells in peripheral blood can indicate transition to AP-CML
	- Anemia
- [[Bone Marrow examination]]
	- Hyperplastic Myelopoiesis  (Increased Granulopoiesis/[[Hematopoiesis]] ratio)
- Cytogenetic testing
- Molecular testing for BCR-ABL before starting treatment with Tyrosine kinase inhibitors

### Complications
- [[Hyperviscosity syndrome]]
- [[Tumor lysis syndrome]]

### Differential diagnosis
- [[Leukemoid reaction]]
- [[polycythemia vera]]
- [[Primary myelofibrosis]]
- [[essential thrombocythemia]]

### Management
- If patient is a candidate for [[Allogenic bone marrow transplantation]], it is the treatment of choice
- If not a candidate,
	- [[tyrosine kinase inhibitors]] like Imatinib 400 mg/day
	- If not remission: Dasatinib
	- Consider: [[α-interferon]] 
- Adjunctive treatment
	- [[Omacetaxine]]
	- [[Hydroxyurea]]
	- [[α-interferon]] 
- [[Stem cell transplantation]] 